HeartCore Announces the Establishment of HeartCore Luvina Vietnam Co., Ltd.
NEW YORK and TOKYO, Feb. 28, 2024 (GLOBE NEWSWIRE) — HeartCore Enterprises, Inc. (Nasdaq: HTCR) (“HeartCore” or “the Company”), a […]
Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering […]
Intelligent Bio Solutions Partners with Cliantha Research to Conduct Clinical Study as Part of FDA 510(k) Pathway
NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) — Intelligent Bio Solutions Inc. (“INBS” or the “Company”) (Nasdaq: INBS), a medical […]
Nano Dimension Announces Important Business Updates:
The Company Plan for the Buy Back of Up to $200 Million of Shares Recently Commenced at Compelling Valuation Levels, […]
Wave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Scheduled for March 6, 2024
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on […]
Cemtrex Issues Shareholder Letter and Provides Corporate Update
Brooklyn, NY, Feb. 28, 2024 (GLOBE NEWSWIRE) — – Cemtrex Inc. (NASDAQ: CETX, CETXP), an advanced security technology and industrial […]
Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD
All animal subjects tolerated maximum dosing Once-per-day human intranasal dosing regimen determined for clinical evaluation SARASOTA, FL, Feb. 28, 2024 […]
Regency Centers Upgraded by Moody’s to an ‘A3’ Credit Rating
JACKSONVILLE, Fla., Feb. 28, 2024 (GLOBE NEWSWIRE) — Regency Centers, L.P. (“Regency Centers”, the “Company” or “Regency”) announced today that […]
Stronghold Digital Mining Sets Fourth Quarter and Full Year 2023 Earnings Conference Call for Wednesday, March 6 at 11:00 a.m. Eastern Time
NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) — Stronghold Digital Mining, Inc. (NASDAQ: SDIG) (“Stronghold”, or the “Company”) will host […]
iCAD Highlights Promising Clinical Data Demonstrating Ability to Reduce Breast Interval Cancer Rates and Decrease Recall Rates at ECR 2024; Showcases Additional Platform Offerings
Clinical evidence demonstrates ProFound Detection’s AI may help reduce breast interval cancer (IC) rates and decrease recall rates without additional […]
